SAN FRANCISCO — On Sunday, Alnylam, the gene-silencing company that notched one gigantic accomplishment after another over the past five years, set out a plan for the next five years built on yet more innovation and growth. At the same time, it announced that quarterly sales of its key drug fell just short of investor expectations.
“We’ve established a sustainable innovation engine, and we’ve coupled this with a very high-performing commercial organization, and this has really driven our growth,” said CEO Yvonne Greenstreet. “When I look forward to the future, I absolutely anticipate that to continue to drive our growth for decades to come.”
Over the next five years, Greenstreet said, Alnylam aims to have the leading franchise in the disease its top-selling drug, Amvuttra, treats; to deliver two medicines in different diseases that could each generate more than a billion dollars in annual sales; and to invest 30% of its sales in research and development. And, she said, it will grow annual sales by 25% a year while maintaining a 30% operating margin excluding one-time costs and other adjustments. Its name for this ambitious plan: Alnylam 2030.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
